title: Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study.
abstract: A prospective multicenter study of cryptococcal immune reconstitution inflammatory syndrome (IRIS) was conducted as a substudy of the Bacteriology and Mycology Study Group 3-01. Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS. No association between the timing of HAART initiation and the diagnosis of IRIS was identified. Increased baseline serum cryptococcal antigen (CrAg) titer was a risk factor for cryptococcal IRIS.
authors.affiliation: Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand. rasuy@mahidol.ac.th
authors.forename: Somnuek
authors.initials: S
authors.lastname: Sungkanuparph
authors.forename: Scott G
authors.initials: SG
authors.lastname: Filler
authors.forename: Ploenchan
authors.initials: P
authors.lastname: Chetchotisakd
authors.forename: Peter G
authors.initials: PG
authors.lastname: Pappas
authors.forename: Tracy L
authors.initials: TL
authors.lastname: Nolen
authors.forename: Weerawat
authors.initials: W
authors.lastname: Manosuthi
authors.forename: Thanomsak
authors.initials: T
authors.lastname: Anekthananon
authors.forename: Michele I
authors.initials: MI
authors.lastname: Morris
authors.forename: Khuanchai
authors.initials: K
authors.lastname: Supparatpinyo
authors.forename: Heather
authors.initials: H
authors.lastname: Kopetskie
authors.forename: Amy S
authors.initials: AS
authors.lastname: Kendrick
authors.forename: Philip C
authors.initials: PC
authors.lastname: Johnson
authors.forename: Jack D
authors.initials: JD
authors.lastname: Sobel
authors.forename: Robert A
authors.initials: RA
authors.lastname: Larsen
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000666:Amphotericin B / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D017322:Clinical Trials, Phase II as Topic; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016867:Immunocompromised Host; D015994:Incidence; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D016919:Meningitis, Cryptococcal / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents; D000935:Antifungal Agents; D000946:Antigens, Fungal; D000666:Amphotericin B; D015725:Fluconazole